LEXX · Lexaria Bioscience Corp. · Executive Compensation
Substantial doubt about the company's ability to continue as a going concern.
“The recurring losses and negative net cash flows raise substantial doubt as to the Company's ability to continue as a going concern. However, we have also concluded that our existing cash, combined with inflows expected from executed license agreements, will not be sufficient to meet the Company's financial obligations for the twelve-month period following the issuance of these consolidated financial statements. Accordingly, there is substantial doubt as to our ability to continue as a going concern within one year from the date of issuance of these financial statements.”View the 10-Q filed Jul 13, 2026
One customer — 100% of revenue (the nine months ended May 31, 2026)
“In the nine months ended May 31, 2026, the Company recognized revenue of $20,000 on a consolidated basis. One customer accounted for 100% of that total.”
2 customers — 100% of revenue (the nine months ended May 31, 2025)
“In the nine months ended May 31, 2025, the Company recognized revenue of $531,923 on a consolidated basis. Two customers accounted for 100% of that total.”
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| John Docherty | President and Chief Scientific Officer (CSO) | Appointed | 2025-01-03 |
| Nelson Cabatuan | Chief Financial Officer | Resigned | 2024-10-02 |
| Michael Shankman | Chief Financial Officer | Appointed | 2024-10-02 |
| Richard Christopher | Chief Executive Officer | Appointed | 2024-09-05 |
| Nelson Cabatuan | Chief Financial Officer | Resigned | 2024-07-17 |
| Nelson Cabatuan | Chief Financial Officer | Appointed | 2024-03-15 |
| Chris Bunka | principal financial officer | Appointed | 2023-06-12 |
| Gregory Downey | Chief Financial Officer | Terminated | 2023-06-12 |
| Catherine C. Turkel | independent director | Appointed | 2022-09-02 |